- Home
- ATAI vs RLAY Comparison
ATAI vs RLAY Comparison
Compare ATAI & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATAI | RLAY |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ATAI | RLAY |
|---|---|---|
| Price | $4.03 | $7.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $13.86 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 4.1M | 2.1M |
| Earning Date | 11-12-2025 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,018,000.00 | ★ $8,355,000.00 |
| Revenue This Year | $962.66 | $19.96 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 811.78 | N/A |
| 52 Week Low | $1.15 | $1.78 |
| 52 Week High | $6.75 | $9.04 |
Technical Indicators
Market Signals| Indicator | ATAI | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 53.35 | 47.97 |
| Support Level | $3.50 | $7.01 |
| Resistance Level | $3.85 | $8.38 |
| Average True Range (ATR) | 0.23 | 0.47 |
| MACD | 0.03 | -0.09 |
| Stochastic Oscillator | 80.43 | 44.55 |
Price Performance
Historical ComparisonAbout ATAI ATAI Life Sciences N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).